Semaglutide Shows Remarkable Results in Adults Over 65 for Weight Loss and Heart Health
New research shows that semaglutide (Ozempic, Wegovy) works exceptionally well in older adults, helping them lose over 15% of body weight on average while improving cardiovascular and metabolic health significantly.
Clinical Findings
A major new analysis suggests semaglutide (Ozempic, Wegovy) works remarkably well in adults over 65, helping many lose substantial amounts of weight while improving heart and metabolic health. Participants taking the drug lost over 15% of their body weight on average — far more than those receiving placebo treatment.
Broader Health Benefits
Many also moved out of obesity categories entirely and reached healthier weight ranges. These improvements extend beyond simple weight loss to include meaningful cardiovascular and metabolic advantages in an older population that historically has been underrepresented in obesity drug trials.
Significance for Aging Population
The finding is particularly significant given that older adults often face unique challenges with weight management and are more vulnerable to obesity-related complications. This study provides evidence that GLP-1 receptor agonists like semaglutide can deliver substantial health improvements in this age group, potentially reducing risks of heart disease and metabolic complications.